U.S. Markets close in 2 hrs 38 mins

Advanced Cell Technology announces third dry AMD patient treated in trial

Advanced Cell Technology announced the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration using retinal pigment epithelial cells derived from human embryonic stem cells. The outpatient transplantation surgery was performed successfully, and the patient is recovering uneventfully. The company's trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry-AMD or Stargardt's macular dystrophy at 12 months, the study’s primary endpoint.